• Manfred Welslau, Andreas D Hartkopf, Volkmar Müller, Achim Wöckel, Michael P Lux, Wolfgang Janni, Johannes Ettl, Diana Lüftner, Erik Belleville, Florian Schütz, Peter A Fasching, Hans-Christian Kolberg, Naiba Nabieva, Friedrich Overkamp, Florin-Andrei Taran, Sara Y Brucker, Markus Wallwiener, Hans Tesch, Andreas Schneeweiss, and Tanja N Fehm.
• Onkologie Aschaffenburg, Aschaffenburg, Germany.
• Geburtsh Frauenheilk. 2019 Oct 1; 79 (10): 1090-1099.

AbstractSignificant advancements have been made in recent years in advanced breast cancer and nearly all of them have been in the field of targeted therapy. Pertuzumab and trastuzumab-emtansine (T-DM1) have been able to be introduced in HER2-positive breast cancer. Now other anti-HER2 therapies are being developed (e.g. margetuximab, DS-8201a, pyrotinib) which can overcome other resistance mechanisms in the HER2 signalling pathway. In the field of hormone-receptor-positive breast cancer, an mTOR inhibitor and CDK4/6 inhibitors were introduced in the past. Now the introduction of the first PI3K inhibitor is forthcoming and this inhibitor will involve genetic testing of the tumour for a mutation in the PIK3CA gene. There are also significant advancements in triple-negative breast cancer: By combining chemotherapy and immunotherapy, an advantage for overall survival was able to be demonstrated in a subgroup (immune cells PD-L1-positive). The PARP inhibitor therapy for HER2-negative patients with a germ line mutation in BRCA1 or BRCA2 was also associated with an improved overall survival in a subgroup. These promising new study results are summarised in this review.

5 keywords...

hide…